Left ventricular hypertrophy (LVH) is highly prevalent in haemodialysis (HD) patients and is associated with an increased risk of death. Roxadustat and recombinant human erythropoietin (rHuEPO, abbreviated as EPO) are the main treatment strategies for renal anaemia in HD patients, but it has not been clear whether there is a difference in their effect on LVH.

中文翻译：

---

在一项随机对照试验中，与 rHuEPO 相比，Roxadustat 可降低血液透析患者的左心室质量指数

左心室肥厚 (LVH) 在血液透析 (HD) 患者中非常普遍，并且与死亡风险增加相关。罗沙司他和重组人促红细胞生成素（rHuEPO，简称EPO）是HD患者肾性贫血的主要治疗策略，但目前尚不清楚它们对LVH的影响是否存在差异。